Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology
Jeffrey S WeberJames Larkin

Abstract

Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma. In this randomised, controlled, open-label, phase 3 trial, we recruited patients at 90 sites in 14 countries. Eligible patients were 18 years or older, had unresectable or metastatic melanoma, and progressed after ipilimumab, or ipilimumab and a BRAF inhibitor if they were BRAF(V 600) mutation-positive. Participating investigators randomly assigned (with an interactive voice response system) patients 2:1 to receive an intravenous infusion of nivolumab 3 mg/kg every 2 weeks or ICC (dacarbazine 1000 mg/m(2) every 3 weeks or paclitaxel 175 mg/m(2) combined with carboplatin area under the curve 6 every 3 weeks) until progression or unacceptable toxic effects. We stratified randomisation by BRAF mutation status, tumour expression of PD-L1, and previous best overall response to ipilimumab. We used permuted blocks (block size of six) within each stratum. Primary endpoi...Continue Reading

References

Apr 12, 2006·The Journal of Experimental Medicine·Mary E KeirArlene H Sharpe
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
May 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberAxel Hauschild
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Nov 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J LipsonSuzanne L Topalian
Feb 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Caroline RobertUNKNOWN MDX010-20 investigators
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jun 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mizuki NishinoF Stephen Hodi
Oct 23, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberY Ann Chen
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto

❮ Previous
Next ❯

Citations

Jan 19, 2016·Future Oncology·Hampig Raphael KourieAhmad Hussein Awada
Feb 5, 2016·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Jingwu Xie, Xiaoli Zhang
Dec 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K A AhmedG T Gibney
Mar 17, 2016·Journal for Immunotherapy of Cancer·Viktor H KoelzerKirsten D Mertz
Jan 20, 2016·Cancers·Bhavana P Singh, April K S Salama
Nov 19, 2015·Expert Review of Anticancer Therapy·Jose C Villasboas, Stephen M Ansell
Jan 20, 2016·Expert Review of Anticancer Therapy·Katrin SchlackLaura-Maria Krabbe
Jan 12, 2016·Expert Opinion on Biological Therapy·Lavinia Spain, James Larkin
Nov 14, 2015·Expert Opinion on Drug Metabolism & Toxicology·C CiccareseF Massari
Feb 13, 2016·Abdominal Radiology·Andrew R BarinaTracy A Jaffe
Jun 4, 2015·Expert Opinion on Biological Therapy·Rosa M Michel Ortega, Harry A Drabkin
Jun 13, 2015·Expert Opinion on Investigational Drugs·Marlana OrloffTakami Sato
Dec 8, 2015·Expert Opinion on Biological Therapy·Antonio Maria GrimaldiPaolo Antonio Ascierto
Feb 11, 2016·Cancer Chemotherapy and Pharmacology·Shruti AgrawalRaymond Darbenzio
Feb 11, 2016·American Journal of Clinical Dermatology·Keiran S M SmalleyVernon K Sondak
Jan 15, 2016·Current Opinion in Immunology·Peter Kar Han LauGrant McArthur
Dec 1, 2015·Critical Reviews in Oncology/hematology·Ryan J DaveyNikola A Bowden
Feb 15, 2016·Cancer Treatment Reviews·Lavinia SpainJames Larkin
Feb 7, 2016·BMC Medicine·Jason M RedmanMichael B Atkins
Jan 26, 2016·Immunotherapy·Sara Valpione, Luca G Campana
Feb 2, 2016·Mayo Clinic Proceedings·Mariah L WhiteSvetomir N Markovic
Jan 29, 2016·Japanese Journal of Clinical Oncology·Susumu SuzukiRyuzo Ueda
Mar 5, 2016·Oncoimmunology·Lorenzo GalluzziGuido Kroemer
Nov 11, 2015·Nature Reviews. Clinical Oncology·Kit Man WongS Gail Eckhardt
Feb 24, 2016·International Journal of Clinical Oncology·Junzo HamanishiIkuo Konishi
Jan 23, 2016·Annales de dermatologie et de vénéréologie·N Meyer
Jan 11, 2016·Journal of Internal Medicine·S MuenstS Hoeller
Nov 26, 2015·Seminars in Oncology·Sanjiv S Agarwala
Nov 12, 2015·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Xiaoli ZhangJingwu Xie
Dec 29, 2015·Critical Reviews in Oncology/hematology·Ziqiang ZhuVladimir Gotlieb
Nov 28, 2015·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Ricarda RauschenbergFriedegund Meier
Dec 8, 2015·Immunotherapy·Takumi KumaiYasuaki Harabuchi
Nov 19, 2015·Molecular Oncology·M H Geukes FoppenJ B A G Haanen
Mar 26, 2016·Frontiers in Oncology·Justine V Cohen, Harriet M Kluger
Jun 28, 2015·The Lancet Oncology·Samantha Bowyer, Paul Lorigan
Dec 2, 2015·Journal of Translational Medicine·Paolo A AsciertoMagdalena Thurin
Sep 12, 2015·Critical Reviews in Oncology/hematology·Matteo S CarlinoHelen Rizos
Oct 11, 2015·HNO·B KansyS Lang
Oct 5, 2015·The Lancet Oncology·Alberto FusiPaolo A Ascierto
Mar 12, 2016·Nature Reviews. Drug Discovery·Axel Hoos
Nov 26, 2015·Seminars in Oncology·Adil Daud

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.